SmartPharm Therapeutics is a cutting-edge brand specializing in biologics and gene-encoded therapeutics. Their innovative approach, known as Gene MAbs™, utilizes gene-encoded antibodies to develop effective treatments for diseases like COVID-19 and lysosomal storage diseases. Unlike traditional viral-vectored gene therapy, SmartPharm's approach offers numerous benefits, including minimal immunogenicity, re-dosability in patients, scalable economic manufacturing, and reduced regulatory complexities.

In recognition of their groundbreaking work, SmartPharm Therapeutics has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to develop a DNA-based neutralizing antibody for intramuscular injection against COVID-19. Their platform technology integrates both DNA and mRNA approaches, allowing them to address a wide range of therapeutic opportunities. With a focus on protective treatment for SARS-CoV-2, eliminating the need for enzyme replacement therapy in lysosomal storage diseases, and developing new treatments for tissue restoration and regeneration, SmartPharm Therapeutics is at the forefront of medical innovation.

Their team consists of experienced leaders in drug development and medical care, ensuring their commitment to excellence and patient wellbeing. Contact SmartPharm Therapeutics today to learn more about their groundbreaking advancements in biologics